ArticleEMBO reports2014
Key challenges for next-generation pharmacogenomics: Science & Society series on Science and Drugs.
Article in EMBO reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- BioSTEM: A modern educational tool for research and innovation in the field of molecular biology and personalized medicine.Human genomics · 2025Article
- Systematic analysis of the pharmacogenomics landscape towards clinical implementation of precision therapeutics in Greece.Human genomics · 2025Article
- Article
- Pharmacogenomics: the low-hanging fruit in the personalized medicine tree.Human genetics · 2022Article
- Whole genome sequencing in oncology: using scenario drafting to explore future developments.BMC cancer · 2021Review
- Adoption of Pharmacogenomic Testing: A Marketing Perspective.Frontiers in pharmacology · 2021Article
- DNA Sequence Analysis in Clinical Medicine, Proceeding Cautiously.Frontiers in molecular biosciences · 2017Review
- A brighter future for the implementation of pharmacogenomic testing.European journal of human genetics : EJHG · 2016Article
- A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.PloS one · 2016Article
- Article
- Global implementation of genomic medicine: We are not alone.Science translational medicine · 2015Review
- Whole genome sequencing in pharmacogenomics.Frontiers in pharmacology · 2015Article
- Causal drift, robust signaling, and complex disease.PloS one · 2015Article
- A call for pharmacogenovigilance and rapid falsification in the age of big data: why not first road test your biomarker?Omics : a journal of integrative biology · 2014Article
- Deciphering next-generation pharmacogenomics: an information technology perspective.Open biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.